🏛️ Verified NIH Record • Updated 2025-12-03
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) (NCT03760575)
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Abramson Cancer Center at Penn Medicine
🩺 Plain-English Summary (8th-Grade Level)
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
Who can join: Review the eligibility criteria below.
Location: Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (215) 662-3914
Email: Corey.Langer@uphs.upenn.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Mesotheliomas Pleural clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.